Doxorubicin/adriamycin and other chemotherapies present with sudden onset hypo or hypertension in up to 60% of patients and rituximab and other monoclonal antibodies present with cutaneous and cardiovascular symptoms in 70% of the patients. This site uses cookies. Keywords: Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. The cumulative incidence of carboplatin-related hypersensitivity was 2% after 8 cycles, 6% after 14 cycles, 8% after 19 cycles, and 10% after 33 cycles, with a plateau beyond this cycle number (Figure 1A). Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. Clinical Practice Guidelines on Supportive Care - ESMO doi: 10.1002/cncr.21168, Dizon, D. S., Sabbatini, P. J., Aghajanian, C., Hensley, M. L., and Spriggs, D. R. (2002). 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. Drafting of manuscript: Y-HT and W-FC. Necessary cookies enable core functionality. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. -. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. All funding for this site is provided directly by ESMO. Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. HemaSphere 6 (3):p e695, March 2022. Galateanu B, Pucau AI, Tircol SA, Tanase BC, Hudita A, Negrei C, Burcea-Dragomiroiu GT, Negreanu L, Vacaroiu IA, Ginghin O. Int J Mol Sci. Desensitization is a high risk procedure in which a drug is administrated to a patient who has already presented an allergic reaction, almost always severe. The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.ESMO-MCBS scores are included in ESMO Clinical Practice Guidelines to help further guide treatment decisions. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. 57 . 2022 Jun 16;3:868300. doi: 10.3389/falgy.2022.868300. LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . Similarly, Kandel et al. A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P. Would you like email updates of new search results? Fu. Allergy Asthma Proc (2011) 32(1):79.10.2500/aap.2011.32.3409 (2009). Table 1. Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. ESMO Virtual Congress 2020 | OncologyPRO With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. ESMO is a Swiss-registered not-for-profit organisation. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. Tx-nave pts ORR was 90%. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Borrs Cuartero J, Farzanegan Miano R, Torres Gorriz MC, Germn Snchez A, Aznar RC, Raducan I, Castell Carrascosa JV, Sanchez Hernandez A, Enrique E. Front Allergy. 57, 163167. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). (2007). ESMO Clinical Practice . Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. and transmitted securely. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Cancer Sci. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). All accepted abstracts are available in theESMO 2017 Abstract Book. Pharmacol. doi: 10.1200/JCO.2009.25.7519, Schwartz, J. R., Bandera, C., Bradley, A., Brard, L., Legare, R., Granai, C. O., et al. Model of in vitro mouse mast cells activation and desensitization. (2015). Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Necessary cookies enable core functionality. S M S, Naveen NR, Rao GK, Gopan G, Chopra H, Park MN, Alshahrani MM, Jose J, Emran TB, Kim B. The cumulative incidence of carboplatin-related hypersensitivity reactions increased with the number of carboplatin cycles (Figure 1A) and increasing dose (Figure 1B), especially at >8 cycles or a dose >3,500 mg. All the statistical tests were two-tailed, and statistical significant level was defined as p-value < 0.05. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Sixty-one of these patients were re-challenged with carboplatin following their initial hypersensitivity reaction. The rate of hypersensitivity to carboplatin did not differ by patient age, menopausal status, disease entity, receipt of optimal debulking, or the amount of ascites. doi: 10.1200/JCO.2006.06.0913, Polyzos, A., Tsavaris, N., Kosmas, C., Arnaouti, T., Kalahanis, N., Tsigris, C., et al. (2010) described the use of cisplatin as an alternative to carboplatin. We also provide recommendations for the continuation of treatment in ovarian cancer patients. (Markman, 2007) reported that carboplatin-related hypersensitivity reactions rarely occur before cycle 6 or <3,000 mg of drug delivery, with the first episode most commonly occurring with carboplatin administration in the second-line setting, and carboplatin administration beyond 9 cycles or 6,000 mg increasing the risk of severe hypersensitivity reactions, similar to our present observations. Patients feel psycho-social impact of chemo m | EurekAlert! See this image and copyright information in PMC. These new ESMO Clinical Practice Guidelines provide tools to evaluate the risk of infusion reactions, to recognise the early signs and symptoms and include recommendations on how to document and manage them. Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice Symptoms and signs of hypersensitivity reactions amendable to desensitization. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. (2010). Emetogenicity of Chemotherapy : MASCC/ESMO Guidelines - EMJ Markman et al. Koshiba et al. CA. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Only 2 women are Mongolians and the other 733 women are Asian Taiwanese. During the study period, our institution applied carboplatin (including carboplatin with cyclophosphamide or paclitaxel) as the front-line chemotherapy for women with ovarian, fallopian tube, and primary peritoneal cancer. Infusion reactions to systemic chemotherapy - UpToDate Int J Med Sci (2011) 8(4):3328.10.7150/ijms.8.332 Compared to women without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly greater median cycle number (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test). (2006). The overall safety profile was similar between subgroups. A three-step method was developed to identify hypersensitivity reactions, including anaphylaxis, in a clinical trial database and could be applied to investigational drugs to improve early detection and monitoring of potential safety concerns, subsequent patient safety management strategies, and potentially programme-wide drug development Educate. We also found higher rates of hypersensitivity among patients with malignant ascites compared to patients without malignant ascites (P = 0.009, chi-squared test), and in patients who had experienced allergic reactions to other medications or food (e.g., paclitaxel, penicillin, aspirin) compared to patients who had not experienced previous allergic reactions (P < 0.001, chi-squared test). Epub 2012 May 3. Ann. (2005). Oncol. Ovarian cancer is the leading cause of death from gynecological malignancies (Chiang et al., 2013), with a 5-year survival rate of 46% in the United States (92% when localized, 73% with regional metastases, and 28% with distant metastases) (Siegel et al., 2016). Similarly, a Japanese study found that carboplatin hypersensitivity occurred at a median of 11.5 cycles and 8,084.5 mg (Koshiba et al., 2009). Gynecol. Disclaimer. Cancer. Table 5. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . Read guidelines by topic Latest Guidelines News Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. 329 (152 CPI-treated v 177 CPI-nave, including 60 tx-nave) pts with RET fusion+ NSCLC were analyzed. LBA10004 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to the June . Shah et al. Author Mariana Castells 1 Affiliation 1 Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. J. Gynecol. ESMO is a Swiss-registered not-for-profit organisation. In our study, 36% of the patients with carboplatin-related hypersensitivity reactions had a history of drug allergies. Management of infusion reactions to systemic anticancer therapy: ESMO The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Necessary cookies enable core functionality. Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. J. Gynecol. This site uses cookies. 2022 Apr 26;14(4):e24515. Met Based Drugs (2010) 2010 Available from: Markman M. Toxicities of the platinum antineoplastic agents. official website and that any information you provide is encrypted The characteristics of the 735 patients are presented in Table 2. (2003) reported that paclitaxel with platinum improves overall survival compared to conventional platinum-based chemotherapy among patients with relapsed platinum-sensitive ovarian cancer. Metrics. Carboplatin and pegylated liposomal doxorubicin (Pujade-Lauraine et al., 2010) or gemcitabine (Pfisterer et al., 2006) led to superior progression-free survival of patients with platinum-sensitive recurrent ovarian cancer compared to paclitaxel and carboplatin. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. 66, 265267. Necessary cookies enable core functionality. 2019 Nov;15(11):e925-e933. doi: 10.3802/jgo.2013.24.4.342, Confino-Cohen, R., Fishman, A., Altaras, M., and Goldberg, A. 2014;24(2):72-9; quiz 2 p following 79. Esmo | Esmo A history of drug or food allergy, the presence of malignant ascites, and the cumulative carboplatin dose are three independent predictive factors of carboplatin hypersensitivity in this survey. Br. Before 8600 Rockville Pike For more detailed information on the cookies we use, please check our Privacy Policy.
esmo 2017 hypersensitivity